Indaptus raises additional $3.4M via convertible notes and warrants, total $5.7M

Indaptus Therapeutics, Inc.

Second closing of private placement adds $3.4M in convertible notes; aggregate gross proceeds now $5.7M.
Notes bear 6% interest, mature July 28, 2026; convert at 80% of 5-day VWAP (max $11.20).
Warrants for 200% of conversion shares, 5-year term, exercise price equal to the conversion price.
Net proceeds to fund Phase 1b/2 clinical trial, R&D, and working capital.
Paulson Investment Company served as exclusive placement agent.

item 1.01item 2.03item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.